INVESTIGATING MULTITARGET POTENTIAL OF MUCUNA PRURIENS AGAINST PARKINSON'S DISEASE: INSIGHTS FROM MOLECULAR DOCKING, MMGBSA, PHARMACOPHORE MODELLING, MD SIMULATIONS AND ADMET ANALYSIS

ZAKIYA FATHIMA C.; JAINEY P. JAMES; MAHENDRA GOWDRU SRINIVASA; SINDHU T. J; MARIYAM JOUHARA B. M.; B. C. REVANASIDDAPPA; SUDEEP D. GHATE

doi:10.22159/ijap.2024v16i5.51474

Authors

ZAKIYA FATHIMA C. Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Deralakatte, Mangaluru-575018, Karnataka, India https://orcid.org/0000-0001-9504-7028
JAINEY P. JAMES Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Deralakatte, Mangaluru-575018, Karnataka, India
MAHENDRA GOWDRU SRINIVASA Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Deralakatte, Mangaluru-575018, Karnataka, India. https://orcid.org/0000-0001-6105-7025
SINDHU T. J Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Deralakatte, Mangaluru-575018, Karnataka, India https://orcid.org/0000-0003-3705-2608
MARIYAM JOUHARA B. M. Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Deralakatte, Mangaluru-575018, Karnataka, India https://orcid.org/0009-0000-7645-0188
B. C. REVANASIDDAPPA Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Deralakatte, Mangaluru-575018, Karnataka, India.
SUDEEP D. GHATE Department of Microbiology, Central Research Laboratory, KS Hegde Medical Academy (KSHEMA), NITTE Deemed to be University, Mangalore-575018, (Karnataka) India

DOI:

https://doi.org/10.22159/ijap.2024v16i5.51474

Keywords:

Mucuna pruriens, Multitarget, Molecular docking, Pharmacophore modeling, Molecular dynamic simulation, Luteolin, Acacetin, Parkinsons disease

Abstract

Objective: Mucuna pruriens (Velvet beans) is a leguminous plant recognised in Vedic therapy as an anti-Parkinsonism agent. The plant is known as the natural reservoir for levodopa. The study aims to evaluate the multitarget inhibitory potency of active constituents present in Mucuna pruriens using in silico tools.

Methods: The phytoconstituents present in Mucuna pruriens were retrieved from the IMPPAT database. The physicochemical and toxicity parameters of phytoconstituents were evaluated using Qikprop and ProTox-3. The inhibitory potential of phytoconstituents on the enzymes Monoamine Oxidase-B (MAO-B), Acetylcholinesterase (AChE), and Catechol-O-Methyltransferase (COMT) was evaluated using in silico techniques, including molecular docking, pharmacophore modelling, and molecular dynamics simulations, conducted with Schrödinger software programs.

Results: The active constituents comply with Lipinski’s rule for drug-likeness. Further, the molecular docking studies revealed the phytoconstituent luteolin and acacetin showed promising multitargeted inhibitory properties. Especially luteolin (-11.504 kcal/mol) and acacetin (-10.620 kcal/mol) have obtained excellent docking scores with MAO-B, whereas the known drug levodopa showed a docking score of-8.501 kcal/mol. The pharmacophore modelling revealed that donor, acceptor, and aromatic features present in luteolin and acacetin are the essential pharmacophoric features accountable for biological activity. The simulation study generated the stability of the protein-ligand complex and found that luteolin showed a stable complex with MAO-B.

Conclusion: Based on these findings, the result of the current study can be used to develop a novel luteolin-based drug for treating Parkinson’s disease with preferred structural modification. However, additional and more comprehensive research is required on this compound.

Downloads

Download data is not yet available.

References

Ouachinou JM, Dassou GH, Idohou R, Adomou AC, Yedomonhan H. National inventory and usage of plant-based medicine to treat gastrointestinal disorders with cattle in Benin (West Africa). S Afr J Bot. 2019;122:432-46. doi: 10.1016/j.sajb.2019.03.037.

Rai SN, Chaturvedi VK, Singh P, Singh BK, Singh MP. Mucuna pruriens in Parkinson’s and in some other diseases: recent advancement and future prospective. 3 Biotech. 2020;10(12):522. doi: 10.1007/s13205-020-02532-7, PMID 33194526.

Lampariello LR, Cortelazzo A, Guerranti R, Sticozzi C, Valacchi G. The magic velvet bean of Mucuna pruriens. J Tradit Complement Med. 2012;2(4):331-9. doi: 10.1016/S2225-4110(16)30119-5, PMID 24716148.

Martinez Leo EE, Martin Ortega AM, Acevedo Fernandez JJ, Moo‐Puc R, Segura Campos MR. Peptides from Mucuna pruriens L., with protection and antioxidant in vitro effect on HeLa cell line. J Sci Food Agric. 2019;99(8):4167-73. doi: 10.1002/jsfa.9649, PMID 30779130.

Guerranti R, Ogueli IG, Bertocci E, Muzzi C, Aguiyi JC, Cianti R. Proteomic analysis of the pathophysiological process involved in the antisnake venom effect of Mucuna pruriens extract. Proteomics. 2008;8(2):402-12. doi: 10.1002/pmic.200700265, PMID 18203263.

Sardjono RE, Khoerunnisa F, Musthopa I, Akasum NS, Rachmawati R. Synthesize, characterization, and anti-Parkinson activity of silver-Indonesian velvet beans (Mucuna pruriens) seed extract nanoparticles (AgMPn). J Phys.: Conf Ser. 2018;1013:012195, doi: 10.1088/1742-6596/1013/1/012195.

Majekodunmi SO, Oyagbemi AA, Umukoro S, Odeku OA. Evaluation of the anti–diabetic properties of Mucuna pruriens seed extract. Asian Pac J Trop Med. 2011;4(8):632-6. doi: 10.1016/S1995-7645(11)60161-2, PMID 21914541.

Golbabapour S, Hajrezaie M, Hassandarvish P, Abdul Majid N, Hadi AH, Nordin N. Acute toxicity and gastroprotective role of M. pruriens in ethanol-induced gastric mucosal injuries in rats. BioMed Res Int. 2013(1):974185. doi: 10.1155/2013/974185, PMID 23781513.

Avoseh ON, Ogunwande IA, Ojenike GO, Mtunzi FM. Volatile composition, toxicity, analgesic, and anti-inflammatory activities of Mucuna pruriens. Nat Prod Commun. 2020;15(7). doi: 10.1177/1934578X20932326.

Okpashi VE, Azuaga TI, Iyen SI, Aikhoje EF, Lajaka JI. Phytochemical screening and antimicrobial activities of leaf extracts of Mucuna pruriens. JOPHAS. OA U. 2019;16(4).

Menon S, Agarwal H, Rajeshkumar S, Kumar SV. Anticancer assessment of biosynthesized silver nanoparticles using Mucuna pruriens seed extract on lung cancer treatment. Res J Pharm Technol. 2018;11(9):3887-91. doi: 10.5958/0974-360X.2018.00712.6.

Suresh S, Prakash S. Effect of Mucuna pruriens (Linn.) on sexual behavior and sperm parameters in streptozotocin-induced diabetic male rat. J Sex Med. 2012;9(12):3066-78. doi: 10.1111/j.1743-6109.2010.01831.x, PMID 20456630.

Pulikkalpura H, Kurup R, Mathew PJ, Baby S. Levodopa in Mucuna pruriens and its degradation. Sci Rep. 2015;5(1):11078. doi: 10.1038/srep11078, PMID 26058043.

Wakabayashi K, Tanji K, Mori F, Takahashi H. The lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of α‐synuclein aggregates. Neuropathology. 2007;27(5):494-506. doi: 10.1111/j.1440-1789.2007.00803.x, PMID 18018486.

Michalska P, León R. When it comes to an end: oxidative stress crosstalk with protein aggregation and neuroinflammation induce neurodegeneration. Antioxidants (Basel). 2020;9(8):740. doi: 10.3390/antiox9080740, PMID 32806679.

Mishra AK, Dixit A. Dopaminergic axons: key recitalists in Parkinson’s disease. Neurochem Res. 2022;47(2):234-48. doi: 10.1007/s11064-021-03464-1, PMID 34637100.

Cheong SL, Federico S, Spalluto G, Klotz KN, Pastorin G. The current status of pharmacotherapy for the treatment of Parkinson’s disease: transition from single-target to multitarget therapy. Drug Discov Today. 2019;24(9):1769-83. doi: 10.1016/j.drudis.2019.05.003, PMID 31102728.

Mathew B, Parambi DG, Mathew GE, Uddin MS, Inasu ST, Kim H. Emerging therapeutic potentials of dual‐acting MAO and AChE inhibitors in Alzheimer’s and Parkinson’s diseases. Arch Pharmazie. 2019;352(11):e1900177. doi: 10.1002/ardp.201900177, PMID 31478569.

Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005;48(21):6523-43. doi: 10.1021/jm058225d, PMID 16220969.

Alov P, Stoimenov H, Lessigiarska I, Pencheva T, Tzvetkov NT, Pajeva I. In silico identification of multi-target ligands as promising hit compounds for neurodegenerative diseases drug development. Int J Mol Sci. 2022;23(21):13650. doi: 10.3390/ijms232113650, PMID 36362434.

James JP, Aiswarya TC, Priya SN, Jyothi DI, Dixit SR. Structure based multitargeted molecular docking analysis of pyrazole-condensed heterocyclics against lung cancer. Int J App Pharm. 2021;3(6):157-69. doi: 10.22159/ijap.2021v13i6.42801.

Nugraha SE, Keliat JM, Marianne SRA. Investigating the toxicity of betalain compounds: in silico analysis and in vivo predictions for standardized Beta vulgaris L. extract. Int J App Pharm. 2024;16(1):118-23. doi: 10.22159/ijap.2024v16i1.49189.

James JP, Pramatha P, Jouhara M, Fathima C Z, D’Souza RR. Green synthesis, multitargeted molecular docking and ADMET studies of chalcones based scaffold as anti-breast cancer agents. Res J Pharm Technol. 2023;16(5):2215-22. doi: 10.52711/0974-360X.2023.00364.

Suwardi S, Salim A, Mahendra JA, Wijayanto DB, Rochiman NA, Anam SK. Virtual screening, pharmacokinetic prediction, molecular docking and dynamics approaches in the search for selective and potent natural molecular inhibitors of MAO-B for the treatment of neurodegenerative diseases. Indo J Chem Env. 2023;6(2):95-110. doi: 10.21831/ijoce.v6i2.68338.

Hosen ME, Rahman MS, Faruqe MO, Khalekuzzaman M, Islam MA, Acharjee UK. Molecular docking and dynamics simulation approach of Camellia sinensis leaf extract derived compounds as potential cholinesterase inhibitors. In Silico Pharmacol. 2023;11(1):14. doi: 10.1007/s40203-023-00151-7, PMID 37255739.

Patel CN, Georrge JJ, Modi KM, Narechania MB, Patel DP, Gonzalez FJ. Pharmacophore-based virtual screening of catechol-O-methyltransferase (COMT) inhibitors to combat Alzheimer’s disease. J Biomol Struct Dyn. 2018;36(15):3938-57. doi: 10.1080/07391102.2017.1404931, PMID 29281938.

James JP, Jyothi D, Priya S. In silico screening of phytoconstituents with antiviral activities against SARS-COV-2 main protease, Nsp12 polymerase, and Nsp13 helicase proteins. Lett Drug Des Discov. 2021;18(8):841-57. doi: 10.2174/1570180818666210317162502.

Mateev E, Georgieva M, Zlatkov A. Improved molecular docking of MAO-B inhibitors with glide. Biointerface Res Appl Chem. 2022;13(2):159. doi: 10.33263/BRIAC132.159.

James P, Ishwar Bhat K, More UA, Joshi SD. Design, synthesis, molecular modeling, and ADMET studies of some pyrazoline derivatives as shikimate kinase inhibitors. Med Chem Res. 2018;27(2):546-59. doi: 10.1007/s00044-017-2081-9.

Malkaje S, Srinivasa MG, Deshpande NS, Navada S, Revanasiddappa BC. An in-silico approach: design, homology modeling, molecular docking, MM/GBSA simulations, and ADMET screening of novel 1,3,4-oxadiazoles as PLK1 inhibitors. Curr Drug Res Rev. 2023;15(1):88-100. doi: 10.2174/2589977514666220821203739, PMID 36017854.

Sachdeo R, Khanwelkar C, Shete A. In silico exploration of berberine as a potential wound healing agent via network pharmacology, molecular docking, and molecular dynamics simulation. Int J App Pharm. 2024;16(2):188-94. doi: 10.22159/ijap.2024v16i2.49922.

Lagunin A, Filimonov D, Poroikov V. Multi-targeted natural products evaluation based on biological activity prediction with pass. Curr Pharm Des. 2010;16(15):1703-17. doi: 10.2174/138161210791164063, PMID 20222853.

T SP, P James J, SR Dwivedi P, Priya S, Fathima CZ, T JS. Synthesis, molecular docking and molecular dynamic studies of thiazolidineones as acetylcholinesterase and butyrylcholinesterase inhibitors. Polycyclic Aromatic Compounds. 2024;44(5):3387-407. doi: 10.1080/10406638.2023.2233666.

James JP, Aziz AA, Krishnan D, Kumar P, Kumar A. Molecular docking and pharmacophore modelling of phytoconstituents of Vaccinium secundiflorum for antidiabetic and antioxidant activity. IJCBDD. 2021;14(5):315-42. doi: 10.1504/IJCBDD.2021.120122.

James JP, Devaraji V, Sasidharan P, Pavan TS. Pharmacophore modeling, 3D QSAR, molecular dynamics studies and virtual screening on pyrazolopyrimidines as anti-breast cancer agents. Polycyclic Aromatic Compounds. 2023 Sep 14;43(8):7456-73. doi: 10.1080/10406638.2022.2135545.

Muralikrishnan A, Kubavat J, Vasava M, Jupudi S, Biju N. Investigation of anti-SARS CoV-2 activity of some tetrahydro curcumin derivatives: an in silico study. Int J App Pharm. 2023;15(1):333-9. doi: 10.22159/ijap.2023v15i1.46288.

Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a web server for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46(W1):W257-63. doi: 10.1093/nar/gky318, PMID 29718510.

Patel S, Modi P, Chhabria M. Rational approach to identify newer caspase-1 inhibitors using pharmacophore-based virtual screening, docking and molecular dynamic simulation studies. J Mol Graph Model. 2018;81:106-15. doi: 10.1016/j.jmgm.2018.02.017, PMID 29549805.

Filimonov DA, Lagunin AA, Gloriozova TA, Rudik AV, Druzhilovskii DS, Pogodin PV. Prediction of the biological activity spectra of organic compounds using the PASS online web resource. Chem Heterocycl Comp. 2014;50(3):444-57. doi: 10.1007/s10593-014-1496-1.

Daina A, Michielin O, Zoete V. Swiss target prediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47(W1):W357-64. doi: 10.1093/nar/gkz382, PMID 31106366.

Goldenberg MM. Medical management of Parkinson’s disease. PT. 2008;33(10):590-606. PMID 19750042.

Rai SN, Birla H, Singh SS, Zahra W, Patil RR, Jadhav JP. Mucuna pruriens protects against MPTP-intoxicated neuroinflammation in Parkinson’s disease through NF-κB/pAKT signaling pathways. Front Aging Neurosci. 2017;9:421. doi: 10.3389/fnagi.2017.00421, PMID 29311905.

Prakash J, Chouhan S, Yadav SK, Westfall S, Rai SN, Singh SP. Withania somnifera alleviates Parkinsonian phenotypes by inhibiting apoptotic pathways in dopaminergic neurons. Neurochem Res. 2014;39(12):2527-36. doi: 10.1007/s11064-014-1443-7, PMID 25403619.

Birla H, Rai SN, Singh SS, Zahra W, Rawat A, Tiwari N. Tinospora cordifolia suppresses neuroinflammation in Parkinsonian mouse model. Neuro Molecular Med. 2019;21(1):42-53. doi: 10.1007/s12017-018-08521-7, PMID 30644041.

Siddique YH. Role of luteolin in overcoming Parkinson’s disease. BioFactors. 2021;47(2):198-206. doi: 10.1002/biof.1706, PMID 33443305.

Ha SK, Moon E, Lee P, Ryu JH, Oh MS, Kim SY. Acacetin attenuates neuroinflammation via regulation the response to LPS stimuli in vitro and in vivo. Neurochem Res. 2012;37(7):1560-7. doi: 10.1007/s11064-012-0751-z, PMID 22447574.

Siddique YH, Jyoti S, Naz F. Protective effect of luteolin on the transgenic Drosophila model of Parkinson’s disease. Braz J Pharm Sci. 2018;54(3):1-13. doi: 10.1590/s2175-97902018000317760.

Huang L, Kim MY, Cho JY. Immunopharmacological activities of luteolin in chronic diseases. Int J Mol Sci. 2023;24(3):2136. doi: 10.3390/ijms24032136, PMID 36768462.

Elmazoglu Z, Yar Saglam AS, Sonmez C, Karasu C. Luteolin protects microglia against rotenone-induced toxicity in a hormetic manner through targeting oxidative stress response, genes associated with Parkinson’s disease and inflammatory pathways. Drug Chem Toxicol. 2020;43(1):96-103. doi: 10.1080/01480545.2018.1504961, PMID 30207190.

Siracusa R, Paterniti I, Impellizzeri D, Cordaro M, Crupi R, Navarra M. The association of palmitoylethanolamide with luteolin decreases neuroinflammation and stimulates autophagy in Parkinson’s disease model. CNS Neurol Disord Drug Targets. 2015;14(10):1350-65. doi: 10.2174/1871527314666150821102823, PMID 26295827.

Reudhabibadh R, Binlateh T, Chonpathompikunlert P, Nonpanya N, Prommeenate P, Chanvorachote P. Suppressing Cdk5 activity by luteolin inhibits MPP+-induced apoptotic of neuroblastoma through Erk/Drp1 and Fak/Akt/GSK3β pathways. Molecules. 2021;26(5):1307. doi: 10.3390/molecules26051307, PMID 33671094.

Ha SK, Moon E, Lee P, Ryu JH, Oh MS, Kim SY. Acacetin attenuates neuroinflammation via regulation the response to LPS stimuli in vitro and in vivo. Neurochem Res. 2012;37(7):1560-7. doi: 10.1007/s11064-012-0751-z, PMID 22447574.

Bu J, Shi S, Wang HQ, Niu XS, Zhao ZF, Wu WD. Acacetin protects against cerebral ischemia-reperfusion injury via the NLRP3 signaling pathway. Neural Regen Res. 2019;14(4):605-12. doi: 10.4103/1673-5374.247465, PMID 30632500.